`Sent:
`
`To:
`
`cara lansden!cambridgefbiogen;nsf;cara.lausden@biogenidec.com;smtp
`Wed Jun 14 2006 17:49:49 EDT
`gi !more o'nei ll/cambridge/biogen@bio ge:lidec;minhua yang/cambridgelbiogen@.biogenidec;-
`
`Subject:
`
`Fw: BG l2 MS IND
`
`To the BG-1 2 MS CDT:
`
`The BG-12 MS IND is no longer on clinical hold! !! Thank you all for your bard work in turning
`around the response so quickJ y.
`
`Regards,
`Ca1a
`
`Cara Lansden
`Sr. Manager, Clinical Development
`Biogen Idee
`Tel +617-679-2658
`Fax +617-679-3518
`Email: cara.lansden@ biogenidec.com
`
`-----Forwarded by Cara Lansden/Cambridge/Biogen on 06/ 14/2006 06:45PM -----
`
`Tammy Samelli/Cambridge/Biogen
`14-.Tun-2006 04:23PM
`Message Size: 2.0 KB
`
`To
`BG- 12 Program Team, Scott Stecher/Cambridge/Biogen@Biogenldec
`cc
`
`Subject
`B G12 MS IND
`
`Page 1 of2
`
`Biogeo Exhibit 2279
`Coalition v. Biogeo
`IPR2015-01993
`
`
`
`Hello evet)'One:
`
`We were notified today by FDA that the clinical hold has been lifted! We are now free to begin
`the QTc study.
`
`Thank you to all of you who worked so hard to make the submission quickly.
`
`Sincerely
`Tammy
`
`Page 2 of2